Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) has announced the pricing of its underwritten public offering in connection with its uplisting to the Nasdaq Capital Market. The offering consists of 2.4 million common shares at a price of US$6.25 per share, with expected gross proceeds of approximately US$15 million. This amount excludes any exercise of the underwriter’s option to purchase up to an additional 360,000 shares. Joseph Gunnar & Co. LLC is acting as sole book-running manager for the offering. Trading on Nasdaq is expected to begin May 20, 2026, under the ticker symbol OPTH.
The company stated that it intends to use the net proceeds from the offering to scale production and distribution of its psychedelic drug products, support market expansion including into the United States, and fund sales growth, working capital, and operating expenses. Optimi also confirmed the effectiveness of its previously announced 1-for-30 share consolidation, resulting in approximately 3.2 million common shares outstanding prior to the offering, subject to rounding and any additional issuances.
Optimi Health is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. The company supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally. Its products are currently prescribed to patients in Australia under the country’s Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.
The uplisting to Nasdaq represents a significant milestone for Optimi, potentially increasing its visibility and access to a broader investor base. The funds raised will be critical for scaling operations and expanding into the U.S. market, which could accelerate the adoption of psychedelic-assisted therapies. This move comes amid growing interest in psychedelic treatments for mental health conditions, such as depression and PTSD, and positions Optimi to meet increasing demand for regulated, GMP-grade products.
The offering and uplisting could have implications for the broader psychedelic pharmaceutical industry, signaling increased capital market confidence in companies that meet rigorous regulatory standards. For investors, the Nasdaq listing provides a more accessible platform to participate in the growth of this emerging sector.
